皮脂腺细胞体外培养及生长调节的研究进展

皮脂腺是皮肤重要的附属器。皮脂腺体外培养模型的建立为研究相关因子如细胞因子、生长激素及药物等对皮脂腺形态功能、生长发育及病理改变的作用提供了良好的平台。本文对皮脂腺细胞体外培养的实验方法、体外生长特性及影响皮脂腺细胞增殖分化的相关因素作简要综述。     

IL-15对儿童MDS造血前体细胞bcl-2、bcl-xl mRNA表达的影响

目的 探讨IL-15对骨髓增生异常综合征(MDS)造血细胞bcl-2、bcl—xl mRNA表达的影响，以探索IL-15抑制MDS CD34^ 造血干／祖细胞凋亡的可能机制：方法 采用吸附单克隆抗体的免疫磁珠分离系统，分离纯化17例MDS患儿骨髓CD34^ 细胞，采用RT—PCR检测bcl-2、bcl—xl mRNA表达水平，观察IL-15对它们的影响。结果 IL-15可呈时间与剂量依赖性的增强体外培养的MDS造血前体细胞bcl-2、bcl—xl基因mRNA的表达。结论 IL-15可能为抑制MDS CD34^ 造血干／祖细胞凋亡的作用机制之一。     

国际疾病分类（ICD）教学的相关问题探讨

国际疾病分类编码是一门重要的医学信息综合性课程,为了提高其教学质量,首先应培养学生的学习的兴趣和主动性;二是在教学过程中,充分与医学基础知识有机地结合的教学方式是提高教学质量重要方法;三是实习和见习是提高学生编码技术的重要步骤。     

Vitapex糊剂在儿童年轻恒牙根尖诱导成形术中的应用

目的探讨Vitapex糊剂和氢氧化钙糊剂用于儿童年轻恒牙根尖诱导成形术的治疗效果。方法对85例儿童,98颗牙根尖发育未完成,牙髓病变已波及根髓、牙髓已坏死或并发根尖周炎的年轻恒牙分为2组,分别用Vitapex糊剂和氢氧化钙糊剂进行根尖诱导成形术,观察其根尖发育情况。结果Vitapex糊剂组总有效率为91.84%。氢氧化钙组总有效率为77.55%。2者疗效在统计学比较存在显著性。结论Vitapex糊剂作为一种根尖诱导成形剂具有良好的治疗效果。值得在临床推广应用。     

儿童血友病429例临床回顾分析

目的探讨血友病患儿确诊时间、症状及其关节畸形等情况。 方法天津血液学研究所血液病医院于1986年7月至2004年8月，对就诊的429例血友病患儿临床症状出现时间、诊断时间及关节畸形出现的时间进行分析。 结果429例血友病患儿，均为男性，血友病A共390例，占909%，其中亚临床型5例(13%),轻型43例(110%)，中型181例(464%)，重型161例(413%)；血友病B共39例，占91%，其中亚临床型2例(51%),轻型6例(154%)，中型26例(667%)，重型5例(128%)。患儿初次出现出血症状的中位年龄为16岁(0~12岁)；但初次诊断年龄03~120岁，中位年龄为52岁(03~120岁)，两者之间差异具有显著性意义(P<001)。 结论目前血友病患儿的诊断存在延迟，替代治疗疗程和因子剂量的不足是关节畸形高发生率的原因。     

中药外敷和泡浴对股骨头缺血性坏死血液流变学的影响

股骨头缺血性坏死属临床难治疾病,如早期不能得到及时有效的治疗,就会使股骨头塌陷,关节间隙变窄,最后导致坏死性骨关节炎,使病人髋关节功能障碍而致残[1-4],所以股骨头坏死的治疗,目前仍是国内外医学界的一大难题.笔者近年来应用中药外敷和泡浴治疗本病168例,并观察了治疗前后血液流变学的变化,现报道如下.     

Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer.

PURPOSE: Tumor necrosis treatment (TNT) uses degenerating tumor cells and necrotic regions of tumors as targets for radioimmunotherapy. Previous studies in animal tumor models and clinical trials have demonstrated that when linked to the therapeutic radionuclide iodine-131, recombinant chimeric TNT antibody ((131)I-chTNT) can deliver therapeutic doses to tumors regardless of the location or type of malignancy. Therapeutic efficacy and toxicity of (131)I-chTNT in advanced lung cancer patients were studied in this pivotal registration trial. PATIENTS AND METHODS: Patients with advanced lung cancer were treated with systemic or intratumoral injection of (131)I-chTNT in eight oncology centers in China. The objective response rate (ORR) was assessed as the primary end point. RESULTS: All 107 patients who were entered onto the study and completed therapy had experienced treatment failure after prior radiotherapy or chemotherapy a mean of three times. The results showed an ORR of 34.6% (complete response, 3.7%; partial response, 30.8%; no change, 55.1%; and progressive disease, 10.3%) in all patients and 33% in 97 non-small-cell lung cancer patients. A biodistribution study demonstrated excellent localization of the radioactivity in tumors in both systemically and intratumorally injected patients. The most obvious adverse side effect was mild and reversible bone marrow suppression. CONCLUSION: Radioimmunotherapy with (131)I-chTNT was well tolerated and can be used systemically or locally to treat refractory tumors of the lung.     

STAT1对人肾透明细胞癌放射敏感性的影响

目的 研究人肾透明细胞癌信号传递和转录活化因子1(STAT1)表达情况及抑制STAT1对该肿瘤细胞放射敏感性的影响.方法 采用免疫组织化学染色技术对比检测34例人肾透明细胞癌标本和12例正常肾组织标本的STAT1表达.用Western blotting法检测离体培养人肾透明细胞癌细胞(CRL-1932)、纤维母细胞(CCL-116)和wilm's瘤细胞(CRL-1441)的STAT1表达.用氟达拉滨和siRNA抑制CRL-1932细胞STAT1表达,并通过成克隆法和台盼蓝染色计数法研究抑制STAT1对CRL-1932细胞放射敏感性的影响.结果 人肾透明细胞癌标本的总STAT1和磷酸化STAT1表达均明显高于正常肾组织.Western blotting法显示CRL-1932细胞STAT1表达比CRL-1441、CCL-116细胞明显增高;药物氟达拉滨能显著抑制CRL-1932细胞磷酸化STAT1的表达,并显著增加CRL-1932细胞的放射敏感性,且放射增敏程度与药物浓度呈正相关.经STAT1 siRNA处理后CRL-1932细胞总STAT1和磷酸化STAT1的表达均被有效抑制,且细胞在照射后的存活分数显著下降.结论 肾透明细胞癌STAT1呈高表达,抑制STAT1对该细胞有放射增敏作用.     

p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.

PURPOSE: Recent studies have highlighted that the p53 codon 72 polymorphism plays a crucial role in modulating wild-type p53 apoptotic capacity, and as such may influence the response to chemotherapy. Thus, the purpose of this study was to investigate whether the p53 codon 72 polymorphism might influence pathologic response to neoadjuvant chemotherapy in primary breast cancer. EXPERIMENTAL DESIGN: One hundred and ten operable breast cancer patients received anthracycline-based neoadjuvant chemotherapy and p53 codon 72 polymorphism status was analyzed by PCR-RFLP. RESULTS: The distribution of initial clinical stage, tumor size, estrogen receptor or progesterone receptor status, menopausal status, or erbB2 expression was not significantly different among the polymorphic variants. However, we found that only 13% (3 of 23) of patients with the Pro/Pro variant had a good pathologic response, defined as a complete pathologic response or minimal residual disease. In comparison, 40% (22 of 55) or 37.5% (12 of 32) of patients with the Pro/Arg or Arg/Arg variant had a good pathologic response (P = 0.019). Moreover, patients with the Pro/Pro variant were more likely to have a positive axillary lymph node status than those with the Pro/Arg or Arg/Arg variant (P = 0.007). Furthermore, in multivariate analysis, p53 codon 72 polymorphism was found to be a strong predictor of pathologic response (odds ratio 6.7, 95% confidence interval, 1.4-31.2; P = 0.016). CONCLUSION: Our study indicates that breast cancer patients with the Pro/Pro variant may be less sensitive to anthracycline-based treatment than those with the Pro/Arg or Arg/Arg variant and suggests that analysis of p53 codon 72 polymorphism may provide a simple predictive marker for selecting the right breast cancer patients to anthracycline-based neoadjuvant chemotherapy in clinical setting.